Targeting inflammatory factors for chemoprevention and cancer interception to tackle malignant mesothelioma

Joseph R. Testa1, Yuwaraj Kadariya1 and Joseph S. Friedberg2

1 Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA

2 Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA

Correspondence to:

Joseph R. Testa, email: [email protected]

Keywords: asbestos; Bap1 mutations; chemoprevention agents; inflammation; preclinical genetically engineered mouse models

Received: May 03, 2024     Accepted: May 08, 2024     Published: May 23, 2024


Mesothelioma is an incurable cancer of the mesothelial lining often caused by exposure to asbestos. Asbestos-induced inflammation is a significant contributing factor in the development of mesothelioma, and genetic factors also play a role in the susceptibility to this rapidly progressive and treatment-resistant malignancy. Consequently, novel approaches are urgently needed to treat mesothelioma and prevent or reduce the overall incidence of this fatal disease. In this research perspective, we review the current state of chemoprevention and cancer interception progress in asbestos-induced mesothelioma. We discuss the different preclinical mouse models used for these investigations and the inflammatory factors that may be potential targets for mesothelioma prevention. Preliminary studies with naturally occurring phytochemicals and synthetic agents are reviewed. Results of previous clinical chemoprevention trials in populations exposed to asbestos and considerations regarding future trials are also presented.

PII: 605